Should all ocular hypertension cases be treated?
October 15th 2005Fort Lauderdale, FL—The management of ocular hypertension has been receiving increased attention since the publication of the Ocular Hypertension Treatment Study (OHTS) results in June 2002. An important area of controversy is what people with ocular hypertension, if anyone, should be treated in the face of treatment costs that approach more than $500/year and the risk of side effects.
Acanthamoeba keratitis potentially devastating
October 15th 2005Washington, DC—Maintaining an index of suspicion for Acanthamoeba infection in patients with keratitis is important, irrespective of a history of contact lens wear, because timely diagnosis and prompt treatment initiation are critical for a good prognosis, said John K. Dart, DM, FRCS, FRCOphth, at World Cornea Congress V.
Cryotherapy: A fall from grace, but not a crash
October 15th 2005That cryotherapy was to be useful in ophthalmology was first shown by Frederich Schoeler (1844-1918) in a German paper, in which he described application of cold carbonic acid crystals to the sclera of rabbits and showed that a lesion of the retina could be produced.
Chance of visual field loss relatively small with ONHD
October 15th 2005Iowa City—The rate of visual field loss in patients who had optic nerve head drusen (ONHD) was about 1.6% per year, approximately what would be expected for this condition, said Andrew G. Lee, MD, professor of ophthalmology, neurology, and neurosurgery at the University of Iowa Hospitals and Clinics, Iowa City.
Dexamethasone implant treats persistent macular edema
October 15th 2005Baltimore—The intravitreal bioerodable dexamethasone implant, evaluated in the Posurdex (Oculex Pharmaceuticals Inc./ Allergan) for Persistent Macular Edema Study, is a drug-delivery system that achieved the primary efficacy outcome, i.e., 2 lines or more improvement in vision 90 days after treatment, with the 700-mg dose.
Evidence-based medicine key to allocation of resources
October 15th 2005The problem with the use of the conversion factor is that physicians are penalized or rewarded based on a sustainable growth rate, which says that the rate of growth of services cannot exceed the growth of the gross domestic product.
Prospective trials needed for venous occlusive disease
October 15th 2005San Francisco—The search for a cure for venous occlusive disease continues but at a slow pace. The last 20 years have seen the introduction of promising medical and surgical therapy for venous occlusive disease. However, the results of prospective trials of these treatments are lacking.
Blue light-filtering IOL may be beneficial
October 15th 2005Montr?al—The blue light-filtering effects in the AcrySof Natural ultraviolet (UV) IOL (Alcon Laboratories) significantly reduce apoptosis of retinal pigment epithelium (RPE) cells induced by blue light compared with the conventional AcrySof filter lens. Implantation of a lens with a blue filter may be beneficial for patients who are at increased risk for the development of macular degeneration.
Will tilt, decentration affect wavefront-corrected IOL result?
October 15th 2005Doubts and concerns regarding efficacy and safety often accompany the introduction of technologies in IOLs. Recent concerns with a wavefront-corrected IOL (Tecnis, Advanced Medical Optics [AMO]) with regard to tilt and decentration are no exception to this rule.
Luscombe joins Aussie laser manufacturer
October 15th 2005Adelaide, Australia—Ophthalmic laser manufacturer Laserex has appointed Simon Luscombe as vice president of sales, Asia, in an effort to increase its Asian market share. Luscombe previously was in product management and sales management positions at Alcon and Advanced Medical Optics.
Alimera Sciences fulfills unmet eye-care needs
October 15th 2005Alpharetta, GA—When the global management of Novartis decided to shut down its ophthalmic operations in Duluth, GA, in early 2003 and relocate to New Jersey, Dan Myers, then president of Novartis Ophthalmics/North America, thought he would leave the company and have the next 6 months to relax.
Effective leadership skills: put to the test in emergencies
October 15th 2005I do not travel much, but recently was excited to represent my department at a special once-in-a-lifetime meeting in Asia. First, I flew to Chicago. A few hundred of us then piled into a 747 at 11 a.m., and the jet taxied out onto the runway. About to take off, we suddenly veered off to the side of the runway, the engines went dead, and fire trucks were visible heading our way.
IntraLASIK yields benefits for conventional and wavefront-guided procedures
October 15th 2005San Francisco—Whether using a conventional ablation technique or CustomCornea (Alcon Laboratories) wavefront-guided procedures, all-laser LASIK (IntraLASIK) performed with femtosecond microkeratome (IntraLase) flap creation affords better efficacy and safety outcomes compared with surgery performed with mechanical microkeratome-created flaps, according to the results of a retrospective study conducted by Ella G. Faktorovich, MD.
Epi-LASIK safe, effective 1 year postop with low patient discomfort
October 15th 2005Lisbon, Portugal—Epi-LASIK is a safe and effective alternative refractive procedure to treat patients with low and moderate levels of myopia, according to Vikentia Katsanevaki, MD, PhD. One-year data indicate that patients have good refractive results and stable vision.
Acute-onset endophthalmitis: what are the risk factors?
October 15th 2005Montr?al—Acute-onset endophthalmitis is an uncommon event after cataract surgery in the new millennium (the rate equals 0.04%). Possible risk factors include intraoperative complications, relative immune compromise, use of lidocaine 2% gel before povidone-iodine preparation, and an inferior location of the incision, according to Harry W. Flynn Jr., MD, at the American Society of Retina Specialists meeting.
Refractive surgery an option for kids with high bilateral myopia
October 15th 2005Orlando—Refractive surgery may be an option for treating children with high myopia and neurobehavioral disorders who are unable to use either of the two principal methods of correcting myopia, spectacles or contact lenses.